Wankowicz SAM, Werner L, Orsola A, Novak J, Bowden M, Choueiri TK, de Torres I, Morote J, Freeman GJ, Signoretti S et al..  2017.  Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.. J Urol. 198(4):817-823.

Gareau DS, Da Rosa JCorrea, Yagerman S, Carucci JA, Gulati N, Hueto F, DeFazio JL, Suárez-Fariñas M, Marghoob A, Krueger JG.  2017.  Digital imaging biomarkers feed machine learning for melanoma screening.. Exp Dermatol. 26(7):615-618.

Chakraborty AA, Nakamura E, Qi J, Creech A, Jaffe JD, Paulk J, Novak JS, Nagulapalli K, McBrayer SK, Cowley GS et al..  2017.  HIF activation causes synthetic lethality between the tumor suppressor and the histone methyltransferase.. Sci Transl Med. 9(398)

Hosono N, Makishima H, Mahfouz R, Przychodzen B, Yoshida K, Jerez A, LaFramboise T, Polprasert C, Clemente MJ, Shiraishi Y et al..  2017.  Recurrent genetic defects on chromosome 5q in myeloid neoplasms.. Oncotarget. 8(4):6483-6495.

Li B, Severson E, Pignon J-C, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S et al..  2016.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.. Genome Biol. 17(1):174.

Becker A, Thakur BKumar, Weiss JMitchell, Kim HSang, Peinado H, Lyden D.  2016.  Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis.. Cancer Cell. 30(6):836-848.

Ross JB, Huh D, Noble LB, Tavazoie SF.  2015.  Identification of molecular determinants of primary and metastatic tumour re-initiation in breast cancer.. Nat Cell Biol. 17(5):651-64.

McKenney ASophia, Levine RL.  2013.  Isocitrate dehydrogenase mutations in leukemia.. J Clin Invest. 123(9):3672-7.

Renwick N, Cekan P, Masry PA, McGeary SE, Miller JB, Hafner M, Li Z, Mihailovic A, Morozov P, Brown M et al..  2013.  Multicolor microRNA FISH effectively differentiates tumor types.. J Clin Invest. 123(6):2694-702.